HomeAI · summaries
Storia in 2 fonti
World's First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory Gastric Cancer and NDA Accepted by China NMPA
World's First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory Gastric Cancer and NDA Accepted by China NMPA
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
World's First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in…
World's First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced…
- ·
endpoints.news
Innovent declares Phase 3 success for gastric cancer ADC that attracted huge Takeda deal
Innovent's CLDN18.2 ADC arcotatug tavatecan hits Phase 3 primary endpoint in gastric cancer, boosting Takeda's $11.4B bet on the drug.